Accelerated approval was based on the Phase 2 RAMP 201 study that demonstrated a 44% overall response rate in patients with KRAS-mutated recurrent low-grade serous ovarian cancer, the company said.

Finding a jury that will listen to the facts and, to the best of their ability, render a fair verdict for a man who is a ...

In the 1990s and 2000s, Sean “Diddy” Combs reigned over American hip-hop. He produced chart-topping albums, launched an ...

A new approach to drug design can deliver medicine directly to the gut in mice at significantly lower doses than current inflammatory bowel disease treatments. The proof-of-concept study introduced a ...

Researchers at The University of Queensland have dosed 5 participants in the first clinical trial of a potentially revolutionary immunotherapy drug to treat Type 1 diabetes. The HER2-targeted ...

Johnson & Johnson (J&J) has reported more data supporting the efficacy of its intravesical drug release system TAR-200 in ...

despite living there when police raided it in June 2021 as part of a drug trafficking investigation. It was the second police raid on the home in 16 months. Desiree Kovacs is facing trial in ...

A common diabetes drug can reduce the pain of people with ... reduced knee arthritis pain over six months in a clinical trial published in JAMA. The randomized clinical trial looked at whether ...

Tagworks Pharmaceuticals announced that the FDA cleared the investigational new drug application for a Phase 1 clinical trial evaluating TGW101. AbbVie submitted its Biologics License Application to ...

Médecins Sans Frontières’ TB-Practecal, a phase 2b-3 randomised controlled trial which identified a new treatment regimen for drug resistant tuberculosis (TB), cost €33.9m (£28.95n; $38.54m), with an ...

is progressing with clinical trials for its lead drug, ENV105, as detailed in a recent letter to shareholders by CEO John Yu, M.D. ENV105 is currently undergoing a Phase 2 trial for prostate ...

Stocktwits - Shares of Summit Therapeutics Inc. (SMMT) surged more than 21% on Wednesday and extended gains in after-hours trading, driven by encouraging results from a late-stage cancer drug trial.